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Background: Type I interferon (IFN) treatment of some cells, including dendritic cells, macrophages and monocytic
THP-1 cells, restricts HIV-1 infection and prevents viral cDNA accumulation. Sterile alpha motif and HD domain
protein 1 (SAMHD1), a dGTP-regulated deoxynucleotide triphosphohydrolase, reduces HIV-1 infectivity in myeloid
cells, likely by limiting dNTPs available for reverse transcription, and has been described as IFNα-inducible. Myeloid
cell infection by HIV-1 is enhanced by HIV-2/SIVSM Vpx, which promotes SAMHD1 degradation, or by exogenous
deoxyribonucleoside (dN) addition.
Findings: SAMHD1 expression was not substantially influenced by IFNα treatment of monocyte-derived
macrophages or THP-1 cells. The contributions of SAMHD1 to the inhibition of HIV-1 infectivity by IFNα were
assessed through the provision of Vpx, exogenous dN addition, or via RNAi-mediated SAMHD1 knock-down. Both
Vpx and dN efficiently restored infection in IFNα-treated macrophages, albeit not to the levels seen with these
treatments in the absence of IFNα. Similarly using differentiated THP-1 cells, the addition of Vpx or dNs, or SAMHD1
knock-down, also stimulated infection, but failing to match the levels observed without IFNα. Neither Vpx addition
nor SAMHD1 knock-down reversed the IFNα-induced blocks to HIV-1 infection seen in dividing U87-MG or THP-1
cells. Therefore, altered SAMHD1 expression or function cannot account for the IFNα-induced restriction to HIV-1
infection seen in many cells and cell lines.
Conclusion: IFNα establishes an anti-HIV-1 phenotype in many cell types, and appears to accomplish this without
potentiating SAMHD1 function. We conclude that additional IFNα-induced suppressors of the early stages of HIV-1
infection await identification.
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Type I interferon (IFN) treatment of some cell types, in-
cluding macrophages, dendritic cells and the monocytic
cell line THP-1, potently induces a block to HIV-1 infection
at the level of viral DNA accumulation [1-4]. The identities
and roles of participating IFN-induced anti-HIV-1 host
factors are yet to be defined. The HIV-2/SIVSM Vpx pro-
tein greatly increases the permissivity of myeloid cells to
HIV-1 infection [5,6]. The protein sterile alpha motif
(SAM) histidine/aspartic acid (HD) domain containing 1
(SAMHD1) was recently identified as a target for Vpx-* Correspondence: michael.malim@kcl.ac.uk
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reproduction in any medium, provided the orinduced proteasomal degradation in monocyte-derived
macrophages (MDMs) and dendritic cells, as well as in
quiescent CD4 T-cells [7-10]. SAMHD1 is a dGTP-
regulated deoxynucleotide triphosphohydrolase that limits
the pool of dNTPs available for reverse transcription,
therefore reducing HIV-1 infection of myeloid cells [11,12];
for a short review see [13]. Interestingly, SAMHD1 has
been reported to be IFNγ- and IFNα-inducible in human
dendritic cells and monocytes, respectively [14,15]. And
consistent with this, it was also shown that Vpx enhances
HIV-1 infection of IFNα-treated monocyte-derived den-
dritic cells [16]. In this context, we sought to investigate
further the role of SAMHD1 in IFNα-induced HIV-1
restriction.
To address the effects of type I IFN on SAMHD1 ex-
pression, we examined a variety of primary cell types andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SAMHD1 is induced poorly by IFNα in monocyte-
derived macrophages. A. 1 to 2 × 106 monocyte-derived
macrophages (MDMs) or primary CD4+ T cells (T cells), PMA-treated
or dividing THP-1 and U937 cells, or U87-MG cells were incubated
(or not) with 1000 U/ml IFNα for 24 h prior to total RNA extraction.
cDNA was synthesized and the relative levels of SAMHD1 expression
(upper panel), as well as two well-known ISGs, ISG15 and APOBEC3A
(lower panel), were analyzed by RT-qPCR and the data were
normalized to both GAPDH and β-actin expression. The graph
shows the data obtained from 3 independent donors for MDMs (#1
#2 #3), and the mean values of relative expression in each cell type,
obtained from 3 independent repetitions with cell lines or 3
different donors for CD4+ T cells. B. Western blot analysis. MDMs
from 2 different donors were treated or not with 1000 U/ml IFNα for
24 h (donor #4), or for 8, 24 and 48 h (donor #5) before cell lysis.
Protein levels of SAMHD1 and APOBEC3A (A3A) were determined,
and tubulin served as a loading control.
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cells, both obtained from multiple donors, dividing and
PMA-treated (differentiated) THP-1 and U937 cells, as
well as U87-MG glioblastoma cells, were treated with
1000 U/ml IFNα for 24 h (for detailed description of
experimental procedures, see Additional file 1). The cells
were harvested for RNA extraction and RT-qPCR, or for
western blot analysis (Figure 1). In MDMs, CD4+ T cells
and dividing THP-1 cells, SAMHD1 was poorly IFNα-
inducible (<2-fold increase in RNA abundance, Figure 1A;
no difference was observed at the protein level for MDMs,
Figure 1B), in contrast to two well-known IFNα-
stimulated genes (ISGs), ISG15 and APOBEC3A [17-20].
In PMA-treated THP-1, untreated U87-MG, as well as in
PMA-treated or dividing U937 cells, SAMHD1 mRNA
levels were modestly upregulated by IFNα treatment
(3- to 5-fold), possibly suggesting a cell type dependent ef-
fect of IFNα on SAMHD1 expression. Of note, U937 cells
expressed more than one order of magnitude lower levels
of SAMHD1 compared to MDMs or THP-1 cells, how-
ever IFNα treatment only increased SAMHD1 RNA levels
by 3- to 5-fold. The IFNα-induced block to HIV-1 infec-
tion is observed in macrophages, PMA-treated and divid-
ing THP-1 cells as well as in U87-MG cells, but not in
U937 cells ([1]; and this manuscript), suggesting that in-
duction of SAMHD1 expression by IFNα does not directly
correlate with a block to HIV-1 infection. However, since
SAMHD1 activity rather than abundance may be
regulated by IFNα, we further investigated a possible role
for SAMHD1 in the IFNα-induced suppression of HIV-1.
As both Vpx-containing virus-like particles (Vpx-VLPs)
as well as exogenous deoxyribonucleosides (dN) relieve
the SAMHD1-mediated HIV-1 block in myeloid cells
[7,8,12], we evaluated the effects of these conditions on
IFNα-treated MDMs (Figure 2). MDMs from 4 independ-
ent donors were treated or not with IFNα for 24 h prior to
infection, and incubated with dN (0.5 or 2.5 mM), or with
Vpx-VLPs, or left untreated (control). The cells were then
infected with increasing amounts of a VSV-G pseudotyped
HIV-1 encoding GFP reporter virus. The percentage of
infected MDMs was enumerated by flow cytometry 2 days
later (Figure 2A displays the mean data and Additional
file 2: Figure S1A separates the data by donor). In agree-
ment with previous reports [5,12,21], both Vpx-VLPs and
exogenous dN increased HIV-1 infectivity in MDMs in
the absence of IFNα (6- to 9-fold and 3- to 8-fold, respect-
ively; Figure 2A). As we reported previously, IFNα treat-
ment decreased HIV-1 infectivity in MDMs by at least
35-fold [1]. Strikingly, both Vpx and 2.5 mM dN efficiently
stimulated HIV-1 infection in IFNα-treated MDMs (by
more than 100-fold at the highest MOI). However, the
levels of infection did not reach the levels observed with-
out IFNα for either condition. Importantly, control VLPs
that lacked Vpx did not have any positive impact on the
Figure 2 Vpx-VLPs or exogenous dN treatment greatly enhance HIV-1 infection in IFNα-treated MDMs. A. VSV-G pseudotyped HIV-1
derived GFP reporter virus was produced in 293T cells and used to infect control or IFNα-treated MDMs at different MOIs (0.08 to 10, as
determined in 293T cells), in the presence or the absence of either Vpx-VLP or 0.5 mM or 2.5 mM deoxyribonucleosides (dN). Levels of infection
were monitored using flow cytometry to measure the percentage of cells expressing GFP, and mean values from 4 independent experiments
(using cells from 4 different donors) are shown. Notably, treatment of MDMs with the higher concentration of dN changed their morphology,
with the cells becoming rounder and less adherent. We conclude that experiments using high dN doses must be analysed with caution. B.
MDMs were treated or not with IFNα for 24 h and subsequently incubated or not with Ctrl-VLPs, Vpx-VLPs or dN (at 0.5 or 2.5 mM as indicated)
for 16 h before lysis. Whole cell dATP was quantified using a single nucleotide quantification assay. Mean values from 4 independent experiments
(using cells from 4 different donors) are shown. C. Western blot analysis. Cell lysates from MDMs (donor #4) were harvested 24 h post IFNα and
Vpx-VLP treatment, and SAMHD1 expression was analysed by western blot; Hsp90 served as a loading control.
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IFNα (Additional file 2: Figure S1A).
The positive effect of both Vpx and dN correlated with
significant increases in the intracellular dNTP pool (as
shown by intracellular dATP measurement, Figure 2B
displays the mean data and Additional file 2: Figure S1B
shows the results for each donor). In agreement with
this finding, Vpx efficiently induced the degradation of
SAMHD1 (Figure 2C). Closer inspection of these data
reveals that dN provision or Vpx addition promote in-
fection to greater magnitudes in cultures treated with
IFNα. While the molecular basis for this is not yet
known, it is plausible that, although its expression is not
increased, SAMHD1 activity might be potentiated in
IFNα-treated MDMs. However, measurement of dATP
levels in the presence or absence of IFNα did not reveal
a significant difference in dATP concentrations, implying
that the dNTP hydrolase activity of SAMHD1 is not
measurably affected by IFNα treatment (Figure 2B and
Additional file 2: Figure S1B). Alternatively, other re-
striction factor(s) might suppress HIV-1 infection more
effectively when cellular dNTP concentrations are low.
Of note, MDMs from different donors behave differentlywith respect to the rescue of HIV-1 infectivity following
dN treatment, suggesting that donor-specific differences
in SAMHD1 levels or activity contribute to differences
in rescue by dN or Vpx (see donors 1 and 2, versus
donors 3 and 4 in Additional file 2: Figure S1).
We next evaluated the effects of dN and Vpx
treatment on IFNα-treated THP-1 cells (Figure 3).
PMA-differentiated THP-1 cells (Figure 3A) or divid-
ing THP-1 cells (Figure 3B) were treated or not with
IFNα for 24 h, and incubated with dN (0.5 mM), or
with Vpx-VLPs, or left untreated (control) before infec-
tion with increasing amounts of a VSV-G pseudotyped
HIV-1 encoding GFP reporter virus. In agreement with
previous reports [12,21], both Vpx-VLPs and exogen-
ous dN increased HIV-1 infectivity in PMA-THP-1
cells in the absence of IFNα (~2-fold; Figure 3A), but
had no significant effect on HIV-1 infection of dividing
THP-1 cells (Figure 3B). As reported previously, IFNα
treatment decreased HIV-1 infectivity in THP-1 cells
by at least 10-fold [1]. In PMA-treated THP-1 cells,
both treatments partially increased HIV-1 infectivity
following IFNα treatment, but had no significant effect
in dividing THP-1 cells. Western blot analysis showed
Figure 3 Vpx-VLPs, exogenous dN treatment or SAMHD1 knock-down do not rescue the IFNα-induced block to HIV-1 infection in THP-
1 cells. A. and B. VSV-G pseudotyped HIV-1 derived GFP reporter virus was produced in 293T cells and used to infect control or IFNα-treated
PMA-differentiated THP-1 cells (A), or dividing THP-1 cells (B) at different MOIs (0.08 to 10), in the presence or the absence of either Vpx-VLP or
0.5 mM deoxyribonucleosides (dN). Levels of infection were monitored using flow cytometry to measure the percentage of cells expressing GFP,
and mean values from 3 independent experiments are shown. C. Western blot analysis. Cell lysates from THP-1 cells were harvested 24 h post
IFNα and Vpx-VLP treatment, and SAMHD1 expression was analysed by western blot; tubulin served as a loading control. D. THP-1 cells
expressing a control shRNA or shRNA targeting SAMHD1 were differentiated with PMA or not in the presence or absence of IFNα for 24 h. Cells
were infected with 3 different doses of VSV-G pseudotyped GFP reporter virus for 48 h, and GFP positive cells were enumerated by flow
cytometry. The data are representative of 3 independent experiments with two independent shRNAs against SAMHD1. E. Western blot analysis of
parallel samples from D. Protein levels of SAMHD1 and APOBEC3A (A3A) were determined and tubulin served as a loading control.
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under all conditions (Figure 3C), indicating that IFNα-
mediated suppression of HIV-1 infection in dividing
and non-dividing THP-1 cells is maintained to signifi-
cant degrees following SAMHD1 removal.
To investigate further the relationship between IFNα
action and SAMHD1 function, we evaluated the effect of
IFNα in THP-1 cells selectively depleted of SAMHD1
under dividing and differentiated culture conditions
(Figure 3D). THP-1 cells were transduced with an HIV-1
shRNA vector targeting SAMHD1, or a control, and
selected with puromycin. Dividing or PMA-treated
shControl or shSAMHD1 THP-1 cells were treated with
IFNα or not for 24 h, and then infected with different
doses of VSV-G pseudotyped HIV-1 GFP vector
(Figure 3D). As previously reported, reducing SAMHD1
protein levels increased the permissivity of PMA-treated
(non-dividing) THP-1 cells by ~4-fold (Figure 3D)
[7,15]. IFNα treatment decreased HIV-1 infectivity by
more than one order of magnitude, irrespective ofwhether SAMHD1 was present or not, or whether the
cells were dividing (Figure 3A and B). Although it is pos-
sible that low residual amounts of SAMHD1 were able
to exert an effect, the data collectively suggest that
SAMHD1 is, if at all, only a minor contributor to the
IFNα-induced early block to HIV-1 infection in these
cells. Of note, similar results were obtained in challenges
with VSV-G pseudotyped full length HIV-1 (not shown).
SAMHD1 is highly expressed in MDMs and THP-1
cells, but to a lower extent in U87-MG cells and we
found that IFNα treatment increased SAMHD1 expres-
sion in U87-MG cells to levels close to those observed
in THP-1 or MDMs (Figure 1A) and western blot ana-
lysis confirmed increased protein levels (Figure 4B). To
test for a cell-type specific activity of SAMHD1 after
IFNα treatment we investigated whether Vpx-VLP treat-
ment would rescue HIV-1 infectivity in IFNα-treated
U87-MG cells. Cultures were treated or not for 24 h
with IFNα, incubated either with Vpx-VLPs, with VLPs
devoid of Vpx (Ctrl-VLPs) or left untreated, and then
Figure 4 SAMHD1 is induced by IFNα in U87-MG cells, but Vpx triggered degradation does not rescue IFNα-mediated HIV-1
suppression. A. U87-MG cells were treated for 24 h with IFNα, or not, and incubated with no VLPs, Vpx-VLPs, or control VLPs (Ctrl-VLPs) and then
infected with increasing amounts of GFP reporter virus (MOI 0.008 to 1), and GFP expression monitored as before. The mean values from 3
independent experiments are shown. B. Western blot analysis of a parallel samples from A. Protein levels of SAMHD1 were determined and
tubulin served as a loading control.
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(Figure 4A). As in myeloid cells (U937 cells excluded),
IFNα treatment decreased HIV-1 infectivity in U87-MG
cells by ~10-fold. Though SAMHD1 was efficiently
degraded by Vpx-VLPs both in the absence or presence
of IFNα (Figure 4B), the effects on HIV-1 infectivity
were minor (maximum 2-fold increase, seen also with
Ctrl-VLPs). In keeping with observations made in divid-
ing THP-1 cells, this further demonstrates that
SAMHD1 degradation does not necessarily correlate
with a rescue of HIV-1 infection, and suggests that
factors distinct from SAMHD1 are involved in the
IFNα-induced block to HIV-1 infection in dividing U87-
MG and THP-1 cells.
In this report, we used several primary and immortalized
cell types to examine the relationship between SAMHD1
expression and function, and the inhibition of HIV-1 infec-
tion by IFNα. Taken together, our data reveal that
SAMHD1, while previously established as an important
regulator of HIV-1 infection [7-10], is not a major effector
of IFNα-mediated HIV-1 restriction in a number of cell
types and lines. In particular, by taking advantage of the
ability of Vpx to degrade SAMHD1 [7,8], dN addition to
bypass its deoxynucleoside triphosphohydrolase activity, or
selective SAMHD1 knock-down, our findings indicate that
IFNα is often able to suppress HIV-1 infectivity independ-
ently of SAMHD1 activity. In keeping with this, several of
our experiments also showed that HIV-1 inhibitory
phenotypes that bear the hallmarks of SAMHD1-mediated
suppression are displayed in differentiated cultures of pri-
mary myeloid cells in the presence or absence of IFNα.
Interestingly, Vpx and dN provoked a substantial increase
in infection of IFNα-treated MDMs, which was greater
than observed in untreated MDMs. This implies that either
SAMHD1 function is at least partly responsible for the
IFNα-mediated restriction in this cell type and/or its ability
to reduce the pool of dNTPs is necessary for the action ofother restriction factor(s). For example, we speculate that
SAMHD1 may allow viral RNA or RNA/DNA reverse
transcription intermediates to be specifically inhibited by
IFNα-induced restriction factors, whilst the presence of
Vpx or dN addition results in these structures being less
abundant (or protected) owing to efficient reverse tran-
scription. Lastly, it has been suggested that Vpx binds to
APOBEC3A (A3A) possibly contributing to increased
HIV-1 infectivity in monocytic cells [22,23]. Although we
cannot rule out a role for A3A in the IFNα-induced block
in MDMs described here, the rescue of HIV-1 infectivity
by dN treatment argues against such a direct role. More-
over, A3A is not induced in U87-MG cells treated with
IFNα, despite a potent block to HIV-1 infection. Our stud-
ies in U87-MG and THP-1 cells, where manipulation of
SAMHD1 fails to overcome the effects of IFNα, allude to
the existence of additional, possibly cell type specific,
IFNα-inducible (and Vpx-independent) inhibitors of the
early stages of HIV-1 infection. Validation of these models
will require the identification of such cell-encoded factors.
Additional files
Additional file 1: Material and methods.
Additional file 2: Figure S1. Vpx-VLPs or exogenous dN treatment
greatly improve HIV-1 infection in IFNα-treated MDMs. A. VSV-G
pseudotyped HIV-1 derived GFP reporter virus was produced in 293T cells
and used to infect control or IFNα-treated MDMs (from four different
donors, donor #1 to #4) at different MOIs (0.08 to 10), in the presence or the
absence of either Vpx-VLP or 0.5 mM or 2.5 mM deoxyribonucleosides (dN).
Levels of infection were monitored using flow cytometry to measure the
percentage of MDMs expressing GFP. B. Single nucleotide–incorporation
analysis of dATP from MDMs treated or not with IFNα for 24 h and
subsequently incubated or not with Ctrl-VLPs, Vpx-VLPs or dN (at 0.5 or 2.5
mM) for 16 h before lysis (+ Ctrl: + dATP; - Ctrl: no dATP).
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